DSGN · Design Therapeutics, Inc.

Track DSGN — free Ask ALVIS about DSGN

$12.02 +0.15 (+1.26%) At close · Jul 29

Market Cap

$750.73M

Shares

62.46M

Design Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Design Therapeutics, Inc. (DSGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts

· $ −$17.71M '25 Q1 25-05-07 · $ −$17.00M '25 Q3 25-11-05 LATEST · $ −$17.64M '26 Q1 26-04-28

Jefferies Global Healthcare Conference

No reported result — non-financial event

Audio Transcript Slides

Design Therapeutics Conference Call

No reported result — non-financial event

Audio Transcript Slides

Design Therapeutics, Inc. Q1 FY2026 Earnings Call

Audio Transcript Slides 8-K10-Q

Design Therapeutics, Inc. Q3 FY2025 Earnings Call

Confident tone Friedreich's Ataxia (FA) clinical data Muscle frataxin expression Study design and disclosure timing

Audio Transcript Slides 8-K10-Q

Design Therapeutics, Inc. Q1 FY2025 Earnings Call

Confident tone mFARS clinical data and dose response Dose exploration beyond 1 MPK Friedreich's Ataxia clinical proof-of-concept

Audio Transcript Slides 8-K10-Q

Design Therapeutics, Inc. Q4 FY2023 Earnings Call

Confident tone Friedreich Ataxia Program (DT-216 / DT-216P2) GeneTAC Platform Differentiation Pharmacokinetics and Formulation Improvements

Results not yet reported

Audio Transcript Slides 8-K10-K

Design Therapeutics, Inc. Q1 FY2022 Earnings Call

Audio Transcript Slides 8-K10-Q

Design Therapeutics, Inc. Q3 FY2021 Earnings Call

Audio Transcript Slides 8-K10-Q

Showing 1–8 of 8 earnings calls

Key facts CIK 1807120 CUSIP 25056L103 13F (30d) 20 filings 20 filers Visit website Investor relations